Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

June 30, 2027

Conditions
OverweightObesityObese Patients
Interventions
DRUG

KDS2010

KDS2010 will be administered orally once daily, three tablets per day, for 12 weeks. Dosage will be either 120 mg or 180 mg depending on the assigned group.

DRUG

Placebo

Placebo matching the investigational product in appearance but containing no active ingredient, administered orally once daily, three tablets per day, for 12 weeks.

Trial Locations (3)

16247

RECRUITING

The Catholic University of Korea, St. Vincent's Hospital, Suwon

03181

RECRUITING

Kangbuk Samsung Medical Center, Seoul

03722

RECRUITING

Yonsei University Health System, Severance Hospital, Seoul

All Listed Sponsors
lead

NeuroBiogen Co., Ltd

INDUSTRY